Transgenomic, Inc. (OTCBB: TBIO) today announced the global, commercial availability of CRC RAScan™, a new mutation detection test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations, identified using the CRC RAScan™ kits which use Surveyor®-Wave® technology, provide physicians with important information regarding tumor mutation status to help with clinical treatment decisions for their mCRC patients. Transgenomic's CLIA-certified laboratory in the United States (U.S.) is available immediately to receive patient samples for testing. In Europe, CE-IVD registered test kits are available for purchase. Research-only test kits will soon be available for purchase in the U.S.
“CRC RAScan is the only dedicated test available today that identifies the full range of RAS mutations to help with treatment decisions for patients with metastatic colorectal cancer.”
The CRC RAScan™ kit was developed in collaboration with Amgen Inc. (NASDAQ: AMGN), and follows discovery of RAS (KRAS and NRAS) mutations in a predefined-retrospective subset analysis of a global, multicenter, randomized Phase 3 study. Results of this analysis will be presented at the 2013 ASCO Annual Meeting on June 4 (Abstract Number 3511; 8:00 a.m. - 12:00 p.m. CDT, S405).
"Our partnership with Amgen, and development of CRC RAScan, supports our goal of developing predictive tests that can help physicians make decisions when selecting treatment options for patients," said Craig Tuttle, Chief Executive Officer of Transgenomic. "CRC RAScan is the only dedicated test available today that identifies the full range of RAS mutations to help with treatment decisions for patients with metastatic colorectal cancer."
Advances in bladder cancer treatments offer hope for curative care